ScholarIQanswers from OpenAlex
Chemotherapy-induced cardiotoxicity and mitigation
TopicLeading institutions, researchers & key papers
Chemotherapy-induced cardiotoxicity and mitigation is a topic indexed in ScholarIQ from OpenAlex.
What is known about Chemotherapy-induced cardiotoxicity and mitigation?
ScholarIQrecord summary
This cluster of papers focuses on the cardiotoxic effects of various cancer treatments, particularly anthracyclines and related drugs like doxorubicin and trastuzumab. It explores the molecular mechanisms, pharmacologic developments, early detection, prevention, and management of cardiotoxicity in cancer patients. The papers also discuss the long-term cardiovascular complications and survival outcomes in individuals undergoing these treatments.
How many works does Chemotherapy-induced cardiotoxicity and mitigation have?
ScholarIQindexed works
Chemotherapy-induced cardiotoxicity and mitigation has 142 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
What is the OpenAlex record for Chemotherapy-induced cardiotoxicity and mitigation?
ScholarIQopenalex
The OpenAlex for Chemotherapy-induced cardiotoxicity and mitigation is on the source record.
What are the most-cited papers on Chemotherapy-induced cardiotoxicity and mitigation?
ScholarIQmost cited works
2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS)
Alexander R. Lyon, Teresa López‐Fernández, Liam S. Couch, Riccardo Asteggiano, Marianne Aznar, Jutta Bergler‐Klein, Giuseppe Boriani, Daniela Cardinale, Raúl Córdoba, Bernard Cosyns, David J. Cutter, Evandro de Azambuja, Rudolf A. de Boer, Susan Dent, Dimitrios Farmakis, Sofie Gevaert, Diana A. Gorog, Joerg Herrmann, Daniel J. Lenihan, Javid J. Moslehi, Brenda Moura, Sonja S Salinger, Richard Stephens, Thomas Suter, Sebastian Szmit, Juan Tamargo, Paaladinesh Thavendiranathan, Carlo G. Tocchetti, Peter van der Meer, Helena J. H. van der Pal, ESC Scientific Document Group, Patrizio Lancellotti, Franck Thuny, Magdy Abdelhamid, Victor Aboyans, Berthe M.P. Aleman, Joachim Alexandre, Ana Barac, Michael A Borger, Rubén Casado-Arroyo, Jennifer Cautela, Jolanta Čelutkienė, Maja Čikeš, Alain Cohen‐Solal, Kreena Dhiman, Stéphane Éderhy, Thor Edvardsen, Laurent Fauchier, Michael G. Fradley, Julia Grapsa, Sigrun Halvorsen, Michael Heuser, Marc Humbert, Tiny Jaarsma, Thomas Kahan, Aleksandra Konradi, Konstantinos C Koskinas, Dipak Kotecha, Bonnie Ky, Ulf Landmesser, Basil S Lewis, Aleš Linhart, Gregory Y H Lip, Maja‐Lisa Løchen, Katarzyna Małaczyńska-Rajpold, Marco Metra, Richard Mindham, Marie Moonen, Tomas G. Neilan, Jens Cosedis Nielsen, Anna-Sonia Petronio, Eva Prescott, Amina Rakisheva, Joe‐Elie Salem, Gianluigi Savarese, Marta Sitges, Jurriën M. ten Berg, Rhian M. Touyz, Agnieszka Tycińska, Matthias Wilhelm, José Luis Zamorano, Nadia Laredj, Parounak Zelveian, Peter P. Rainer, Fuad Samadov, Uladzimir Andrushchuk, Bernhard Gerber, Mirsad Selimović, Elena Kinova, Jure Samardžić, Evagoras Economides, Radek Pudil, Kirsten M Nielsen, Tarek A Kafafy, Riina Vettus, Suvi Tuohinen, Stéphane Éderhy, Zurab Pagava, Tienush Rassaf, Αlexandros Briasoulis
Doxorubicin pathways
Caroline F. Thorn, Connie Oshiro, Sharon Marsh, Tina Hernandez‐Boussard, Howard L. McLeod, Teri E. Klein, Russ B. Altman
Cardiac Dysfunction in the Trastuzumab Clinical Trials Experience
Andrew D. Seidman, Clifford A. Hudis, Mary Kathryn Pierri, Steven Shak, Virginia Paton, Mark Ashby, Maureen Murphy, Stanford J. Stewart, Deborah Keefe
Management of cardiac disease in cancer patients throughout oncological treatment: ESMO consensus recommendations
Giuseppe Curigliano, Daniel J. Lenihan, Michael G. Fradley, Sarju Ganatra, Ana Barac, Anne Blaes, J. Herrmann, Charles Porter, Alexander R. Lyon, P Lancellotti, Aarti Patel, Jeanne M. DeCara, Joshua D. Mitchell, Eric Harrison, Javid J. Moslehi, Ronald Witteles, Maria Grazia Calabró, Roberto Orecchia, Evandro de Azambuja, J. L. Zamorano, Ronald J. Krone, Zaza Iakobishvili, Joseph R. Carver, Saro H. Armenian, Bonnie Ky, Daniela Cardinale, Carlo M. Cipolla, Susan Dent, Karin Jordan
Assessment of Echocardiography and Biomarkers for the Extended Prediction of Cardiotoxicity in Patients Treated With Anthracyclines, Taxanes, and Trastuzumab
Heloisa Sawaya, Igal A. Sebag, Juan Carlos Plana, James L. Januzzi, Bonnie Ky, Timothy C. Tan, Victor Cohen, José Banchs, Joseph R. Carver, Susan E. Wiegers, Randolph P. Martin, Michael H. Picard, Robert E. Gerszten, Elkan F. Halpern, Jonathan Passeri, Irene Kuter, Marielle Scherrer‐Crosbie
Where is Chemotherapy-induced cardiotoxicity and mitigation research published, and who funds it?
ScholarIQvenues & funding sources
TOP JOURNALS
TOP FUNDERS
National Science Foundation—
NIH—
Wellcome Trust—
European Research Council—
Funder breakdown is a member featureSign up free to unlock
How much of the research on Chemotherapy-induced cardiotoxicity and mitigation is open access?
ScholarIQopen access share
73%OPEN ACCESS